BioVie Analyst Ratings
BioVie Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
08/22/2023 | 211.61% | Cantor Fitzgerald | → $11 | Reiterates | Overweight → Overweight |
07/18/2023 | 211.61% | Cantor Fitzgerald | → $11 | Reiterates | Overweight → Overweight |
05/17/2023 | 211.61% | Cantor Fitzgerald | → $11 | Reiterates | Overweight → Overweight |
05/17/2023 | 239.94% | Oppenheimer | → $12 | Reiterates | Outperform → Outperform |
02/14/2023 | 239.94% | Oppenheimer | → $12 | Reiterates | → Outperform |
09/28/2022 | 126.63% | EF Hutton | $14 → $8 | Maintains | Buy |
07/22/2022 | 98.3% | Cantor Fitzgerald | → $7 | Initiates Coverage On | → Overweight |
03/17/2022 | 296.6% | EF Hutton | $9 → $14 | Maintains | Buy |
03/15/2022 | 154.96% | Oppenheimer | → $9 | Initiates Coverage On | → Outperform |
11/30/2021 | 664.87% | B. Riley Securities | $50 → $27 | Maintains | Buy |
01/15/2021 | 1231.44% | B. Riley FBR | → $47 | Initiates Coverage On | → Buy |
日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
---|---|---|---|---|---|
2023年08月22日 | 211.61% | 康托·菲茨杰拉德 | →$11 | 重申 | 超重→超重 |
07/18/2023 | 211.61% | 康托·菲茨杰拉德 | →$11 | 重申 | 超重→超重 |
2023年05月17日 | 211.61% | 康托·菲茨杰拉德 | →$11 | 重申 | 超重→超重 |
2023年05月17日 | 239.94% | 奥本海默 | →$12 | 重申 | 跑赢→跑赢大盘 |
02/14/2023 | 239.94% | 奥本海默 | →$12 | 重申 | →跑赢大盘 |
09/28/2022 | 126.63% | EF Hutton | $14→$8 | 维护 | 买 |
07/22/2022 | 98.3% | 康托·菲茨杰拉德 | →$7 | 开始承保 | →超重 |
03/17/2022 | 296.6% | EF Hutton | $9→$14 | 维护 | 买 |
03/15/2022 | 154.96% | 奥本海默 | →$9 | 开始承保 | →跑赢大盘 |
2021年11月30日 | 664.87% | B.莱利证券 | $50→$27 | 维护 | 买 |
2021/01/15 | 1231.44% | B.莱利FBR | →$47 | 开始承保 | →购买 |
What is the target price for BioVie (BIVI)?
BioVie(BIVI)的目标价格是多少?
The latest price target for BioVie (NASDAQ: BIVI) was reported by Cantor Fitzgerald on August 22, 2023. The analyst firm set a price target for $11.00 expecting BIVI to rise to within 12 months (a possible 211.61% upside). 6 analyst firms have reported ratings in the last year.
2023年8月22日,坎托·菲茨杰拉德报道了BioVie(纳斯达克:BIVI)的最新目标价。这家分析公司将目标价定为11美元,预计BIVI将在12个月内升至(可能上涨211.61%)。6家分析公司在过去一年公布了评级。
What is the most recent analyst rating for BioVie (BIVI)?
BioVie(BIVI)的最新分析师评级是多少?
The latest analyst rating for BioVie (NASDAQ: BIVI) was provided by Cantor Fitzgerald, and BioVie reiterated their overweight rating.
分析师对BioVie(纳斯达克代码:BIVI)的最新评级由康托·菲茨杰拉德提供,BioVie重申其增持评级。
When is the next analyst rating going to be posted or updated for BioVie (BIVI)?
BioVie(BIVI)的下一次分析师评级将于何时发布或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioVie, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioVie was filed on August 22, 2023 so you should expect the next rating to be made available sometime around August 22, 2024.
分析师在进行了广泛的研究后得出了股票评级,其中包括查阅公共财务报表,与BioVie的高管和客户交谈,以及听取收益电话会议。大多数分析师每三个月就会这样做一次,所以你每年应该会得到每家公司每家公司的4个评级。BioVie的上一次评级是在2023年8月22日提交的,所以你应该预计下一次评级将在2024年8月22日左右提供。
Is the Analyst Rating BioVie (BIVI) correct?
分析师对BioVie(BIVI)的评级正确吗?
While ratings are subjective and will change, the latest BioVie (BIVI) rating was a reiterated with a price target of $0.00 to $11.00. The current price BioVie (BIVI) is trading at is $3.53, which is within the analyst's predicted range.
虽然评级是主观的,并将发生变化,但最新的BioVie(BIVI)评级被重申,目标价在0.00美元至11.00美元之间。BioVie(BIVI)目前的交易价格为3.53美元,在分析师的预测范围内。